IMVT AI Price Prediction
Track IMVT's AI-powered predictions, market trends, and investment insights.
Mock Tradesimulated, no real money
You don't hold IMVT in your mock portfolio yet.
Track IMVT's AI-powered predictions, market trends, and investment insights.
You don't hold IMVT in your mock portfolio yet.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get StartedImmunovant remains in a loss-making phase, as reflected by its negative EPS of -2.77 and a negative PE ratio of -11.23. This indicates the company is still in a development or early commercialization stage, relying on investor capital rather than internally generated profits.
The stock’s recent 7.5% gain over the last month and its current price of $31.11 trading well above the 200-day moving average of $23.75 suggest a positive technical trend. This positioning typically indicates sustained upward momentum and constructive investor sentiment.
Alternative data signals are mixed and relatively muted in magnitude. Web traffic of about 10,245 visitors per month is modest, and job openings have declined by 14.3% month over month, which can suggest more cautious growth or cost discipline rather than active expansion.
Immunovant’s stock shows bullish technical momentum but is underpinned by a fundamentally loss-making profile and only modest alternative data signals. Overall, the setup appears balanced between upside potential driven by sentiment and pipeline expectations and downside risk tied to ongoing losses and limited operational scale.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy
Immunovant (IMVT) is trading at $31.61 on NASDAQ, posting a 2.6% single-session gain on volume of over 1.68 million shares — a signal of active institutional and retail interest. With a market capitalization of $6.5 billion, the clinical-stage biopharmaceutical company commands significant investor attention for a pre-revenue biotech. The price action reflects growing confidence in Immunovant's pipeline centered on batoclimab, its lead FcRn-targeting monoclonal antibody being evaluated across multiple autoimmune indications including myasthenia gravis, thyroid eye disease, and warm autoimmune hemolytic anemia.
TrendEdge's AI assigns IMVT a score of 7 out of 10, indicating a moderately bullish outlook supported by identifiable positive signals. For a clinical-stage biotech, a 7/10 reflects the meaningful upside potential embedded in batoclimab's multi-indication pipeline while acknowledging the binary risk typical of Phase II-stage assets. The score likely incorporates the positive price momentum seen today, healthy trading volume relative to the company's stage, and the strategic value of FcRn inhibition as a validated mechanism in autoimmune disease — a space that has seen significant M&A and commercial validation from competing programs.
The most critical catalysts to monitor for IMVT in 2026 are clinical readouts from batoclimab's Phase IIa trials in myasthenia gravis and thyroid eye disease, alongside data from the Phase II warm autoimmune hemolytic anemia study. Positive efficacy and safety data could materially reprice the stock upward. Key risks include trial failure, safety signals specific to FcRn inhibition, and the competitive pressure from already-approved FcRn inhibitors. Cash runway and potential dilution remain standard watch items for any clinical-stage company.
Unlock comprehensive alternative data signals to make better investment decisions
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Web Traffic
10,327
LinkedIn Followers
19,850
Job Postings
5
LinkedIn Employees
307
News Mentions
1
Key Metrics
